A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (0518-019)

• Status: Completed
• Trial end date: 2011-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will investigate the safety and efficacy of raltegravir as a therapy for Human Immunodeficiency Virus (HIV)-infected patients failing current therapy with 3-class antiviral resistance.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Raltegravir Potassium

Criteria

Inclusion Criteria:

• Patient must be HIV positive with HIV RNA values that are within ranges required by the study

• Patient must have documented failure of certain antiretroviral therapy

• Patient must be on the same antiretroviral therapy for at least the past two months

Exclusion Criteria:

• Patient less than 16 years old

• Additional study criteria will be discussed and identified by the study doctor